BLS Pharmaceuticals (ASX: BLS) reported a standout FY26 with revenue surging 161% to $74.2 million and net profit more than tripling to $15.4 million, driven by expanded manufacturing and major international contracts including a $50 million German supply deal.
- 161% revenue growth to $74.2 million
- Net profit after tax up 214% to $15.4 million
- Secured $50 million two-year German supply agreement
- Expanded manufacturing footprint in Australia, UK, and Latin America
- FY27 revenue guidance of $105–115 million with continued international expansion
Record Revenue and Profit Fuel BLS’s International Expansion
BLS Pharmaceuticals (ASX:BLS) has cemented its transformation from a microcap life sciences player into a global pharmaceutical manufacturer with a blockbuster FY26 performance. The company reported a 161% leap in revenue to $74.2 million and a 214% surge in net profit after tax to $15.4 million, both hitting the top end of upgraded guidance ranges. This surge was underpinned by a ramp-up in manufacturing volumes, an expanded product and customer base, and a growing international footprint.
The company’s adjusted EBITDA climbed 171% to $19 million, representing a healthy margin of 26%, reflecting improved operating leverage as BLS scaled its Australian manufacturing hub and broadened its commercial reach.
$50 Million German Supply Deal Highlights International Breakthrough
A major highlight was BLS’s two-year pharmaceutical supply agreement with Germany’s ADREXpharma, valued at approximately $50 million, including a $25 million minimum purchase commitment in the first 12 months. This deal grants ADREXpharma exclusive rights to distribute BLS’s Dr Watson® medicinal cannabis products in Germany, Europe’s largest medicinal cannabis market. This contract marks one of the most significant commercial supply agreements secured by BLS to date and validates its ability to deploy Australian-developed manufacturing and quality systems in a large, regulated European market.
In addition, BLS commenced manufacturing for Nasdaq-listed Aurora Cannabis, initially producing medicinal cannabis oils for Australia with plans to expand into vape products across Australia, the UK, and Germany. The company also established its presence in Latin America, making its first commercial supply into Costa Rica through a distribution agreement with Remidose LATAM SRL.
Building Manufacturing Capacity in Australia and the UK
Australia remains the cornerstone of BLS’s operations, with its Brisbane GMP-licensed facility supporting over 30 dosage forms across medicinal cannabis, MDMA, and psilocybin. The facility’s estimated annual revenue capacity exceeds $250 million, providing ample room for growth through increased utilisation without proportionate capital expenditure.
Internationally, BLS is advancing its GMP pharmaceutical manufacturing facility in the Scottish Borders, supported by $1.7 million in non-dilutive funding from South of Scotland Enterprise. Construction began in February 2026 with licensing targeted by December 2026, aiming to expand manufacturing capacity and facilitate direct supply into the UK and European markets.
Strategic Rebranding and Capital Management
FY26 also saw BLS complete a corporate rebrand from Bioxyne to BLS Pharmaceuticals, aligning its listed identity with its core pharmaceutical manufacturing business. The company conducted a 1-for-10 share consolidation to better position itself for institutional and international investors.
Despite significant investment in inventory, rising from $3.6 million to $17.8 million to support forecast demand and continuity of supply, BLS maintained positive operating cash flow of $5.4 million and ended the year with $13.3 million in cash. The Board emphasized disciplined capital allocation, balancing growth investments with working capital management and regulatory compliance across multiple jurisdictions.
Outlook: FY27 Guidance and Growth Priorities
Looking ahead, BLS targets FY27 revenue of $105 million to $115 million, representing growth of 42% to 55%, with an adjusted EBITDA margin guidance of 23% to 26%. The company plans to leverage existing Australian manufacturing capacity, execute on international contracts including the German supply deal, and bring its UK GMP facility online by year-end to bolster European market access.
CEO Sam Watson highlighted the strong foundation built in FY26 and reiterated the focus on execution and sustained value creation: "We enter FY27 with more manufacturing capacity, better market access, bigger contracts and more opportunities than ever before." The company is also advancing proprietary drug development programs targeting chronic mental health conditions, including PTSD and treatment-resistant depression, reflecting growing global acceptance of cannabis, MDMA, and psilocybin-based medicines.
With a multi-jurisdictional licence stack, expanding international partnerships, and a diversified product portfolio, BLS is poised to capitalise on evolving regulatory landscapes and increasing patient demand across Australia, Europe, the UK, and Latin America.
Investors will be watching how BLS converts its substantial inventory and working capital investments into recurring revenue and cash flow, and how swiftly the UK manufacturing facility secures licensing and ramps up production.
Record quarterly revenue and operating cash flow and $50 million pharmaceutical supply deal underscore BLS’s growing international momentum and operational scale.
Bottom Line?
BLS enters FY27 on a strong footing with robust contracts and manufacturing capacity, but execution risks remain around UK licensing and converting inventory into cash flow.
Questions in the middle?
- How quickly will BLS secure full licensing and commercial production at its UK GMP facility?
- Can BLS sustain margin expansion while scaling international contracts and managing working capital?
- What progress will BLS make in clinical development and commercialisation of proprietary psychedelic medicines?